Biotech, articles on Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech, articles on

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jongmans who wrote ()	6/6/2000 6:46:00 AM
From: sim1	of 36

From Signals... Pharma's New Vision One of the main take-home messages from Allicense 2000, which convened in Basel Switzerland May 2-4, was this: Thanks to the tremendous amount of data pouring forth from genome sequencing efforts, the traditional bottleneck in drug discovery -- not enough new targets -- has been eliminated. But it hasn't disappeared, it's just moved, for now it's a question of picking the right target as a drug development candidate. It's too early to tell whether the abundance of new targets will have a measurable impact on overall R&D productivity. The major pharmaceutical houses are still shifting gears: Through their alliances with biotech firms and universities as well as their own in-house initiatives, they're in the process of integrating entirely new discovery technologies -- from functional assays to ultra-high throughput screens -- into their drug development programs. <snip> recap.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next